A Clinical Trial to Evaluate the Pharmacokinetics and Safety of AD-230 in Healthy Adults

Phase 1Not Yet RecruitingNCT07521241

Addpharma Inc.52 enrolled

Overview

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Chronic Liver Disease (CLD)

Interventions

AD-230, AD-2301DRUG

Oral administration of AD-230 or AD-2301, according to randomized sequence.

Eligibility

Sex: ALLMin age: 19 YearsMax age: 64 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * \- Body mass index (BMI) between 18.5 kg/m2 and 29.9 kg/m2 at the time of screening visit * Subjects aged 19 years or older and under 65 years at the screening visit Exclusion Criteria: * Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration * Other exclusions applied

Locations (1)

Kyungpook National university hospital

Seoul, South Korea

Outcomes

Primary Outcomes

AUClast

Time frame: -24hours to 72hours

Cmax

Time frame: -24hours to 72hours

Central Contacts

Sarah Yoon

CONTACT

031-891-5576 sryoon@addpharma.co.kr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.